Key Highlights

  • Dr. Morana Jovan‑Embiricos resigned from the board and audit committee on July 3 2026, citing no disagreement with the company.
  • Laurie Keating will receive an option to buy 18,000 KLRS shares, with monthly vesting over three years, and cash compensation of $40,000 plus $7,500 for audit duties.
  • Keating’s indemnification agreement, protects her against certain legal expenses arising from board service.

Kalaris Therapeutics, Inc. (NASDAQ: KLRS) disclosed a shift in its board composition on July 3 2026. The company confirmed that Dr. Morana Jovan‑Embiricos stepped down from both the board and its audit committee, and that Laurie Keating was elected to replace her effective August 1 2026.

Board Resignation

The departure of Dr. Jovan‑Embiricos was presented as immediate and unrelated to any operational dispute. Her exit opened a vacancy on the audit committee, prompting the board to act swiftly to fill both roles.

New Board Member

Laurie Keating was selected to join the board as a Class I director, with her service extending until the 2027 annual shareholders’ meeting. The nomination committee identified her as a suitable candidate based on her experience, and she does not have familial connections to current directors or executives.

Audit Committee Assignment

Starting August 1 2026, Keating also assumed duties on the audit committee, inheriting the responsibilities previously held by Dr. Jovan‑Embiricos. The committee’s remit includes oversight of financial reporting, internal controls, and compliance functions, which are critical to KLRS governance.

Director Compensation

Pursuant to Kalaris’ non‑employee director policy, Keating will be granted an option to acquire 18,000 KLRS shares at the market price on the date of the award. The option will vest in equal monthly portions over a three‑year period, with acceleration provisions in the event of a change‑in‑control. In addition, she will be paid an annual cash retainer of $40,000 for board participation and a supplemental $7,500 for audit committee service.

Standard equity awards and reimbursement for travel related to board duties are also provided. The agreement obligates the company to reimburse her for permitted expenses, including legal fees, that may arise from her role as a director.

Sector Context and Outlook

Kalaris Therapeutics operates within the biotechnology sector, where strong board oversight is essential for navigating regulatory pathways, clinical development milestones, and financing needs. The addition of a director with audit expertise supports the company’s commitment to transparent financial reporting and risk management, which are key considerations for investors in this space.

Impact on KLRS

The leadership change introduces fresh oversight while preserving continuity in audit functions. Investors can anticipate that the board’s composition will remain stable through the 2027 shareholder meeting, with Keating’s compensation structured to align her interests with those of KLRS shareholders.

FAQs

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.